MYELODYSPLASTIC SYNDROMES

This study tests an experimental drug called AG-946 (tebapivat) in 87 adults with lower-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if the drug can raise hemoglobin levels or help patients go without blood transfusions for at least 8 weeks. The study …

This study tests whether the oral drug Inqovi can reduce the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) coming back after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will take Inqovi as maintenance th…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to lower the risk of graft-versus-host disease, a common complication. The goal is to see i…

This study tests a drug called luspatercept in 70 adults with a low-risk form of MDS that causes severe anemia. The goal is to see if the drug can reduce or eliminate the need for regular red blood cell transfusions. Participants receive the drug and are monitored for safety and …

This study compares an oral medication (ASTX727) to a standard IV drug (decitabine) for treating myelodysplastic syndromes (MDS), a bone marrow disorder. About 72 Chinese adults with MDS will take both treatments in a crossover design to see if the pill works as well as the IV. T…

This study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to gather long-term safety information. About …

This study tests whether eltrombopag, a drug that boosts platelet production, can help adults with lower-risk myelodysplastic syndromes (MDS) who regularly need platelet transfusions. About 36 participants in Japan will receive either eltrombopag or a placebo to see if they can g…

This study tests a new approach for people with leukemia or myelodysplastic syndromes (MDS) who need a donor stem cell transplant. Before the transplant, patients receive a special type of radiation (helical tomotherapy) along with two chemotherapy drugs (fludarabine and melphala…

This study tests whether adding a precise, high-dose radiation to the marrow (total marrow irradiation) to standard chemotherapy before a donor stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) live longer without …

This study tests whether a new drug called luspatercept works better than a standard drug (epoetin alfa) for treating anemia in adults with a certain type of bone marrow disorder (lower-risk MDS). Participants have not needed blood transfusions or prior anemia treatments. The goa…

This early-phase trial tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a stem cell transplant. The treatment combines a special donor cell infusion with an immunotherapy drug (ipilimumab) to fight the cancer. The main goal is to find the s…

This early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like leukemia and myelofibrosis. The goal is to find a safe dose that controls the disease. Sixteen adults aged 18 and older are …

This early-phase study tests a new way to do stem cell transplants for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors add special immune cells (regulatory T-cells) to the transplant to help the body accept the new…

This study tests whether giving a drug that affects gene activity (epigenetic priming) before standard chemotherapy is safe and effective for children with newly diagnosed acute myeloid leukemia (AML). About 206 participants will receive either azacitidine or decitabine for five …

This study tests a drug called luspatercept in adults with lower-risk myelodysplastic syndromes (MDS) or related blood disorders who have anemia. The goal is to see if it can reduce the need for regular blood transfusions. Six participants will receive the drug along with standar…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This study tests whether adding the drug vorinostat to standard care can lower the chance of graft-versus-host disease (GVHD) in children, teens, and young adults getting a bone marrow or blood stem cell transplant for blood cancers. About 43 participants will receive vorinostat …

This study tested a bone marrow transplant using frozen, banked bone marrow from unrelated donors for people with blood cancers like leukemia. The goal was to see if it safely restores healthy blood cells and controls the disease. The trial was withdrawn before enrolling any part…

This study tests a new drug called bexmarilimab combined with standard treatments for people with certain blood cancers (MDS, CMML, or AML). The goal is to find a safe dose and see if the combination helps control the disease. About 181 adults will take part, and the study is cur…

This study tests a stem cell transplant method that filters out certain immune cells (TCRαβ+ and CD19+) from a half-matched family donor's blood. The goal is to lower the risk of graft-versus-host disease, a serious complication, and allow patients to avoid long-term immune-suppr…

This study tests a chemotherapy drug called CPX-351 in 20 adults aged 18-70 with high-risk myelodysplastic syndrome (MDS) who are eligible for a stem cell transplant. The main goal is to see if the drug is safe and tolerable at two different dose levels. Researchers will also tra…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease. About 313 adults with various blood cancers…

This study tests whether stem cells from donated umbilical cords are safe and can help people with myelodysplastic syndrome (MDS), a bone marrow disorder. About 40 adults with moderate to severe MDS will receive the stem cells and be watched for side effects and improvement. The …

This study tests a device that filters out certain immune cells from donor blood before a stem cell transplant. The goal is to lower the risk of graft-versus-host disease, a serious complication where the donor cells attack the patient's body. About 50 adults with myelodysplastic…

This study tests a drug called imetelstat in people with a bone marrow disorder (MDS) who currently need regular blood transfusions. The goal is to see if the drug can help them go without transfusions for at least 8 weeks. About 289 adults with low- or intermediate-risk MDS that…

This study tests whether an oral chemotherapy drug (ONUREG) can help people with low- or intermediate-risk myelodysplastic syndrome (MDS), a blood disorder. About 230 participants will receive either the drug or a placebo, plus standard supportive care. The goal is to see if the …

This early-phase study tests whether the drug itacitinib can prevent a serious complication called cytokine release syndrome (CRS) after a stem cell transplant in people aged 60 and older with blood cancers. The study involves 32 participants who receive a 'mini' transplant from …

This study tests whether starting luspatercept at the highest approved dose can help people with low-risk myelodysplastic syndromes (MDS) go without red blood cell transfusions for at least 8 weeks. About 106 adults who currently need regular transfusions will receive the drug an…

This study follows people with myelodysplastic syndromes or chronic myelomonocytic leukemia who already benefited from the drug sabatolimab in an earlier trial. The goal is to collect more safety information over time, not to test a new treatment. About 33 participants will conti…

This study tests a combination of two drugs, canakinumab and darbepoetin alfa, in people with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS) who no longer respond to standard treatment. The goal is to see if the combination is safe and can reduce…

This study tests a program that combines mindfulness and music therapy, delivered through an app or website, to help people who are getting a stem cell transplant feel better and have a higher quality of life. About 60 adults with certain blood cancers will try the program during…

This study looks at whether adding a palliative care team to standard leukemia treatment helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life care. About 320 patients receiving non-intensive therapy will take par…

This study looks at how blood cancers and stem cell transplants affect muscle function in 144 patients. Researchers want to see if muscle health can help predict complications like infections, relapse, or survival. The goal is to better understand the role of muscle strength at k…

This study looks at whether a lab test can predict how well chemotherapy will work for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Researchers will take blood samples before treatment and test them in the lab to see if the results match how patien…

This study enrolls 120 people with different cancers who already received treatment in an earlier study. The goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.

This study was designed to learn how the protein calprotectin might change blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare stem cells from patients with severe or moderate COVID-19, those with chronic myeloid malignancies, …

This study aims to understand the genetic and molecular changes that occur in people with bone marrow failure disorders, such as aplastic anemia and myelodysplastic syndromes. Researchers will analyze blood and bone marrow samples from up to 1,400 participants aged 2 and older, i…

This study follows 300 people who have low blood cell counts (cytopenia) lasting at least 4 months but do not yet have myelodysplastic syndromes (MDS). The goal is to see how often these early conditions, called ICUS and CCUS, turn into MDS. Participants are observed over time, a…

This study aims to uncover the genetic causes of blood and bone marrow cancers by analyzing samples from 5,000 participants. Researchers will look for specific cell abnormalities that drive cancer growth and test whether existing drugs can reverse them. The goal is to develop gen…

This study looks at how common acquired pyruvate kinase deficiency is in people with certain blood cancers or pre-cancer conditions. Researchers will take a single blood sample from 100 participants to check for low enzyme activity or gene changes. The goal is to better understan…